PE20241617A1 - Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva - Google Patents

Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva

Info

Publication number
PE20241617A1
PE20241617A1 PE2023003445A PE2023003445A PE20241617A1 PE 20241617 A1 PE20241617 A1 PE 20241617A1 PE 2023003445 A PE2023003445 A PE 2023003445A PE 2023003445 A PE2023003445 A PE 2023003445A PE 20241617 A1 PE20241617 A1 PE 20241617A1
Authority
PE
Peru
Prior art keywords
atp
methods
cognitive function
compositions containing
adenosine triphosphate
Prior art date
Application number
PE2023003445A
Other languages
English (en)
Spanish (es)
Inventor
John Rathmacher
Larry Kolb
Shawn Baier
Original Assignee
Tsi Usa Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsi Usa Llc filed Critical Tsi Usa Llc
Publication of PE20241617A1 publication Critical patent/PE20241617A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PE2023003445A 2021-06-22 2022-06-22 Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva PE20241617A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163213378P 2021-06-22 2021-06-22
PCT/US2022/034510 WO2022271813A1 (en) 2021-06-22 2022-06-22 Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function

Publications (1)

Publication Number Publication Date
PE20241617A1 true PE20241617A1 (es) 2024-08-07

Family

ID=84544774

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003445A PE20241617A1 (es) 2021-06-22 2022-06-22 Composiciones que contienen adenosin trifosfato (atp) y metodos de uso para la funcion cognitiva

Country Status (12)

Country Link
US (1) US20240299435A1 (cg-RX-API-DMAC10.html)
EP (1) EP4358972A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024524288A (cg-RX-API-DMAC10.html)
CN (1) CN117835985A (cg-RX-API-DMAC10.html)
AU (1) AU2022297444A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224861A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003882A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000517A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP24004256A (cg-RX-API-DMAC10.html)
MX (1) MX2024000145A (cg-RX-API-DMAC10.html)
PE (1) PE20241617A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022271813A1 (cg-RX-API-DMAC10.html)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095695A (ja) * 1998-07-23 2000-04-04 Nippon Koutai Kenkyusho:Kk 精神分裂病治療薬
US20030069203A1 (en) * 2001-06-04 2003-04-10 Lee Steve S. Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
US7629329B2 (en) * 2001-06-04 2009-12-08 Tsi Health Sciences, Inc. Method for increasing muscle mass and strength through administration of adenosine triphosphate
US20050261239A1 (en) * 2004-05-23 2005-11-24 Universiteit Van Maastricht Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
KR101424833B1 (ko) * 2006-06-27 2014-08-01 코와 가부시키가이샤 피로 예방 및/또는 회복을 위한 의약
US9522161B2 (en) * 2010-10-26 2016-12-20 Advanced Bio Development, Inc. Performance enhancing composition and method of delivering nutrients
CN113142581B (zh) * 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
US20140044690A1 (en) * 2012-08-08 2014-02-13 University Of South Florida High-Energy Compounds for Use in Alzheimer's and Other Neurodegenerative Diseases
BR112015005199B1 (pt) * 2012-09-10 2022-09-06 Metabolic Technologies, Inc Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo
WO2014106860A2 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US10888576B2 (en) * 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
WO2021046357A1 (en) * 2019-09-05 2021-03-11 Jiangyin Tsi Pharmaceutical Co., Ltd. Compositions containing adenosine triphosphate (atp) and methods of use

Also Published As

Publication number Publication date
CA3224861A1 (en) 2022-12-29
CN117835985A (zh) 2024-04-05
CO2024000517A2 (es) 2024-05-10
AU2022297444A1 (en) 2024-01-18
US20240299435A1 (en) 2024-09-12
EP4358972A4 (en) 2025-04-16
ECSP24004256A (es) 2024-02-29
EP4358972A1 (en) 2024-05-01
WO2022271813A1 (en) 2022-12-29
CL2023003882A1 (es) 2024-07-05
MX2024000145A (es) 2024-03-22
JP2024524288A (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
CO2025009073A2 (es) Compuestos cíclicos fusionados y uso de los mismos
GT199900119A (es) Jarabe antihistaminico estabilizado.
MX9305769A (es) Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
CR8402A (es) Indazol-o-glucosidos sustitutos
ES2163076T3 (es) Composiciones antitumorales que contienen derivados del taxano.
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
ES2051772T3 (es) 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
ES2059491T3 (es) Derivados de indol con anillos condensados.
CY1111843T1 (el) 2-υποκατεστημενα αναλογα βιταμινης d και θεραπευτικες χρησεις αυτων
ES2137512T3 (es) Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico.
UY38332A (es) Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos
PY2201650A (es) Nuevos derivados de espirociclohexano, composiciones farmacéuticas que los contienen y sus usos como inhibidores antiapoptóticos
ES2000502A6 (es) Un procedimiento para la preparacion de poli-4-aminopirrol-2-carboxamido derivados
ES2039200T3 (es) Derivados isotiazolonicos.
ES2074505T3 (es) Pomada que contiene propionato de deprodona.
CO2023011641A2 (es) Compuestos químicos
CL2023003882A1 (es) Composiciones que contienen adenosín trifosfato (atp) y métodos de uso para la función cognitiva
AR033702A1 (es) Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del vih
ES8301216A1 (es) Un procedimiento para la preparacion de derivados de enantolactama.
ES2058150T3 (es) Procedimiento para la obtencion de productos de reaccion del 2,2-bis(4-hidroxifenil)hexafluorpropano asi como estos nuevos derivados.
ES2192495B1 (es) Nuevo uso terapeutico del ribosido de 5-aminoimidazol-4-carboxamida (acadesina).
AR134453A1 (es) Inhibidores de cbl-b y métodos de uso de los mismos
AR021577A1 (es) Preparado con una amplitud terapeutica mejorada, que contiene inhibidores de la sintesis de los nucleotidos
AR029305A1 (es) Benzolsulfonilureas y -tioureas 2,5-sustituidas, procedimiento para su preparacion, y preparados farmaceuticos que las contienen